These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33184233)

  • 21. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
    Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
    Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactive Associations of Vascular Risk and β-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals: Findings From the Harvard Aging Brain Study.
    Rabin JS; Schultz AP; Hedden T; Viswanathan A; Marshall GA; Kilpatrick E; Klein H; Buckley RF; Yang HS; Properzi M; Rao V; Kirn DR; Papp KV; Rentz DM; Johnson KA; Sperling RA; Chhatwal JP
    JAMA Neurol; 2018 Sep; 75(9):1124-1131. PubMed ID: 29799986
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study.
    Kim JW; Byun MS; Yi D; Lee JH; Ko K; Jeon SY; Sohn BK; Lee JY; Kim YK; Shin SA; Sohn CH; Lee DY;
    PLoS Med; 2020 Feb; 17(2):e1003022. PubMed ID: 32097439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE
    JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
    de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
    Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Elevated Amyloid Levels With Cognition and Biomarkers in Cognitively Normal People From the Community.
    Petersen RC; Wiste HJ; Weigand SD; Rocca WA; Roberts RO; Mielke MM; Lowe VJ; Knopman DS; Pankratz VS; Machulda MM; Geda YE; Jack CR
    JAMA Neurol; 2016 Jan; 73(1):85-92. PubMed ID: 26595683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality.
    Lopez OL; Becker JT; Chang Y; Klunk WE; Mathis C; Price J; Aizenstein HJ; Snitz B; Cohen AD; DeKosky ST; Ikonomovic M; Kamboh MI; Kuller LH
    Neurology; 2018 May; 90(21):e1920-e1928. PubMed ID: 29695596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
    Winer JR; Maass A; Pressman P; Stiver J; Schonhaut DR; Baker SL; Kramer J; Rabinovici GD; Jagust WJ
    JAMA Neurol; 2018 Feb; 75(2):227-235. PubMed ID: 29228071
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationships between performance on the Cogstate Brief Battery, neurodegeneration, and Aβ accumulation in cognitively normal older adults and adults with MCI.
    Lim YY; Pietrzak RH; Bourgeat P; Ames D; Ellis KA; Rembach A; Harrington K; Salvado O; Martins RN; Snyder PJ; Masters CL; Rowe CC; Villemagne VL; Maruff P
    Arch Clin Neuropsychol; 2015 Feb; 30(1):49-58. PubMed ID: 25467942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between educational attainment and amyloid deposition across the spectrum from normal cognition to dementia: neuroimaging evidence for protection and compensation.
    Arenaza-Urquijo EM; Bejanin A; Gonneaud J; Wirth M; La Joie R; Mutlu J; Gaubert M; Landeau B; de la Sayette V; Eustache F; Chételat G
    Neurobiol Aging; 2017 Nov; 59():72-79. PubMed ID: 28764930
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Higashi T; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Okina T; Suzuki N; Hasegawa H; Nagahama Y; Ishizu K; Oishi N; Kimura H; Watanabe H; Ono M; Saji H; Yamauchi H
    Ann Nucl Med; 2018 Apr; 32(3):206-216. PubMed ID: 29388083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
    Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
    JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early detection of amyloid load using
    Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M
    Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia.
    Zhao Y; Tudorascu DL; Lopez OL; Cohen AD; Mathis CA; Aizenstein HJ; Price JC; Kuller LH; Kamboh MI; DeKosky ST; Klunk WE; Snitz BE
    JAMA Neurol; 2018 Jan; 75(1):88-96. PubMed ID: 29114732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease.
    Jack CR; Wiste HJ; Vemuri P; Weigand SD; Senjem ML; Zeng G; Bernstein MA; Gunter JL; Pankratz VS; Aisen PS; Weiner MW; Petersen RC; Shaw LM; Trojanowski JQ; Knopman DS;
    Brain; 2010 Nov; 133(11):3336-48. PubMed ID: 20935035
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Visual and Quantitative Florbetapir F 18 Positron Emission Tomography Analysis in Predicting Mild Cognitive Impairment Outcomes.
    Schreiber S; Landau SM; Fero A; Schreiber F; Jagust WJ;
    JAMA Neurol; 2015 Oct; 72(10):1183-90. PubMed ID: 26280102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Trajectory of Clinical and Biomarker Changes in Sporadic Alzheimer's Disease.
    Zhuo J; Zhang Y; Liu Y; Liu B; Zhou X; Bartlett PF; Jiang T;
    Cereb Cortex; 2021 Jun; 31(7):3363-3373. PubMed ID: 33690839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.